Artivion shares detracted from performance in the second quarter after the company modestly lowered its full-year outlook, primarily due to slower-than-expected starter set sales for AMDS, its key new product cycle. The medical device maker reported in-line first-quarter results but the guidance cut weighed on the stock, according to the Alger Weatherbie Specialized Growth Fund's Q2 2026 investor letter. Artivion closed at $25.37 per share on July 20, 2026, with a one-month return of 22.68% and a 52-week loss of 16.55%, giving it a market capitalization of $1.23 billion. The fund noted that the Industrials and Information Technology sectors contributed to relative performance, while Financials and Consumer Discretionary detracted.
Artivion IncSlower-than-expected starter set sales for AMDS, its key new product, led to a lowered full-year outlook.